Avant Diagnostics Inc. AVDX Archives - Page 2 of 2

WednesdayOct 21, 2015 4:14 pm

Avant Diagnostics, Inc. (AVDX) Preparing to Commence Pivotal Validation Study for OvaDx®

October is international breast cancer awareness month, but it’s also a great time to take a look at the effects that other types of cancer have on the global population. Each year, over 20,000 women in the United States are diagnosed with ovarian cancer, and more than 14,000 women die from the devastating disease. According to the Centers for Disease Control and Prevention, despite accounting for just three percent of all cancers in women, ovarian cancer causes more deaths than any other cancer of the female reproductive system. The key to surviving ovarian cancer, according to the National Cancer Institute,…

ThursdayOct 15, 2015 2:10 pm

Avant Diagnostics, Inc. (AVDX) Leads Development in Early Ovarian Cancer Detection Technology

Great strides in medical technology are being undertaken by Avant Diagnostics, a company that focuses its developments on the human genome project, which aims to map out the entire DNA sequence of a human. Innovations in this endeavor may treat, prevent, and cure disease as scientists will have a blueprint of how humans have developed over time along with what genes lead to illness. The company hopes to develop genetic research that can detect illness early in individuals so that treatment can avert progression or death. With this goal in mind, Avant Diagnostics has developed the first large panel biomarker…

WednesdayOct 07, 2015 9:25 am

Avant Diagnostics Inc. (AVDX) Announces FDA IRB Approval for OvaDx(R) Ovarian Cancer Validation Test Specimens

Avant Diagnostics, an innovative in vitro diagnostics company, today told investors that the previously purchased specimens have been approved and are available for use in the upcoming validation study to be used to support a pre-Submission package to the United States Food and Drug Administration (“FDA”). Avant anticipates that the FDA validation study will start shortly after the ongoing calibration testing is completed. Upon completion, Avant intends to test the previously purchased set of ovarian cancer specimens, including serial sets obtained from women diagnosed previously with ovarian cancer, which will serve as the validation study and form the basis of…

TuesdayOct 06, 2015 2:25 pm

Avant Diagnostics, Inc. (AVDX) Advancing Development of OvaDx® through Ongoing Calibration Testing

Avant Diagnostics, Inc. has commenced calibration testing of OvaDx®, a sophisticated microarray-based test that measures the activation of the immune system in blood samples in response to ovarian tumor cell development. In a recent news release, the company indicated that it expects to complete this calibration testing later this month, allowing it to move forward with validation testing while forming the basis of the pre-submission package that will be delivered to the U.S. Food and Drug Administration for review and comment prior to the commencement of the OvaDx® 510(k) trial. “The entire Avant team has been working tirelessly over the…

TuesdaySep 29, 2015 4:44 pm

Avant Diagnostics, Inc. (AVDX) Offers the Market’s First Large-Panel Screening Test for Ovarian Cancer

Avant Diagnostics, based in Scottsdale, Arizona, is a medical diagnostic company specializing in large panel biomarker screening. OvaDx is the company’s first test, a sophisticated microarray-based way to detect pre-symptomatic ovarian cancer by measuring the activation of the immune system in blood samples in response to early stage ovarian tumor cell development. Identifying the variations of specific genes in the genome is an expanding objective of genetic research, since variations are what define individual characteristics, including disease states or a statistical propensity for disease. Early detection of disease can provide options for earlier treatments that may improve the patient’s chances…

ThursdaySep 24, 2015 11:39 am

Avant Diagnostics, Inc. (AVDX) Begins OvaDx® Ovarian Cancer Test Calibration Necessary for FDA Submission

Avant Diagnostics, an innovator in molecular diagnostics, this morning announced the start of calibration testing in preparation for the company’s validation study of OvaDx®, which will be used to support a pre-submission package to the United States Food and Drug Administration ("FDA"). Avant expects to complete the calibration testing within 30 days. OvaDx® is a sophisticated microarray-based test proposed for use in monitoring women previously diagnosed with ovarian cancer. Pre-clinical research studies with OvaDx® indicate high sensitivity and specificity for all types and stages of ovarian cancer. Upon completion of the testing, Avant said it intends to test the previously…

MondaySep 21, 2015 12:47 pm

Avant Diagnostics, Inc. (AVDX) is “One to Watch”

Avant Diagnostics is a medical diagnostic technology company that specializes in large panel biomarker screening. The company's first test, OvaDx®, is a sophisticated microarray-based test designed to detect pre-symptomatic ovarian cancer by measuring the activation of the immune system in blood samples in response to early stage ovarian tumor cell development. In clinical development, OvaDx has indicated high sensitivity and specificity for all types and stages of ovarian cancer, including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous and ovarian adenocarcinoma. Upon FDA approval, Avant plans to offer its diagnostic product as an elective test for women…

Site Search

Company Search

Tag: Avant Diagnostics Inc. AVDX